FibroBiologicsFBLG
FBLG
About: FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.
Employees: 8
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
109% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 11
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
3% more funds holding
Funds holding: 61 [Q3] → 63 (+2) [Q4]
1.58% more ownership
Funds ownership: 15.56% [Q3] → 17.14% (+1.58%) [Q4]
29% less capital invested
Capital invested by funds: $16.8M [Q3] → $11.9M (-$4.94M) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$12
1,088%
upside
Avg. target
$14
1,286%
upside
High target
$16
1,484%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert 26% 1-year accuracy 72 / 279 met price target | 1,484%upside $16 | Buy Maintained | 4 Mar 2025 |
HC Wainwright & Co. Matthew Caufield 26% 1-year accuracy 16 / 62 met price target | 1,088%upside $12 | Buy Reiterated | 13 Feb 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics
This innovative method has the potential to unlock new treatment options for chronic conditions driven by mitochondrial dysregulation.
Neutral
GlobeNewsWire
2 weeks ago
FibroBiologics and Charles River Announce Completion and Release of CYWC628 Master Cell Bank for the Manufacturing of Fibroblast Cell-based Wound Healing Therapeutic
Master cell bank to be used in manufacturing of CYWC628 drug product to support upcoming clinical trial for diabetic foot ulcers Master cell bank to be used in manufacturing of CYWC628 drug product to support upcoming clinical trial for diabetic foot ulcers
Neutral
GlobeNewsWire
1 month ago
FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates
HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it will host an in-person analyst day at the New York Marriott Marquis on February 12, 2025, at 2:00 p.m. ET. The event will feature presentations from the following members of the Company's management: Pete O'Heeron, Chief Executive Officer Hamid Khoja, PhD, Chief Scientific Officer Robert Hoffman, Interim Chief Financial Officer The event will highlight FibroBiologics' research and development strategy for advancing fibroblast-based therapeutics to address chronic diseases.
Neutral
GlobeNewsWire
2 months ago
FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing
HOUSTON, Dec. 30, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it has closed the second $5 million tranche of the previously announced Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, LTD. (“Yorkville”), an investment fund managed by Yorkville Advisors Global, LP. The agreement allows FibroBiologics, subject to customary conditions, to sell up to $25 million in the aggregate of its common stock to Yorkville over the course of two years.
Neutral
GlobeNewsWire
2 months ago
D. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its $25.0 Million Financing
HOUSTON, Dec. 30, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it has entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN LTD. (“Yorkville”), an investment fund managed by Yorkville Advisors Global, LP. The agreement allows FibroBiologics, subject to customary conditions, to sell up to $25 million in the aggregate of its common stock to Yorkville over the course of two years.
Neutral
GlobeNewsWire
2 months ago
FibroBiologics Announces $25 Million Financing
HOUSTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced that it has entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN LTD. (“Yorkville”), an investment fund managed by Yorkville Advisors Global, LP. The agreement allows FibroBiologics, subject to customary conditions, to sell up to $25 million in the aggregate of its common stock to Yorkville over the course of two years.
Neutral
GlobeNewsWire
3 months ago
FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly
HOUSTON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application covering methods for treatment of splenomegaly using a cell-based therapeutic approach.
Neutral
GlobeNewsWire
3 months ago
FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics
HOUSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application with the United States Patent and Trademark Office covering methods employing fibroblasts or other Tissue Factor (TF)-expressing cells to prevent IBMIR-mediated blood clotting.
Neutral
GlobeNewsWire
3 months ago
FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the second quarter of 2025
Neutral
GlobeNewsWire
4 months ago
FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology
HOUSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced promising new findings from its artificial thymus organoid program. Recent results from the artificial thymus organoid program showed that fibroblasts and thymus-derived cell organoids can persist and function for over 50 days post-transplantation, with vascularization and the generation of a diverse array of mature T cells in animal models.
Charts implemented using Lightweight Charts™